Activating KRAS mutations are associated with poor prognosis in patients with non-small cell lung cancers (NSCLCs), and KRAS mutant NSCLC tumors are often resistant to common anti-cancer drugs. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.